Skip to main content
AIDS (London, England)
Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status.
Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.
Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase.
Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates.
Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure.
Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection.
Select host restriction factors are associated with HIV persistence during antiretroviral therapy.
Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cd-NF-?B signaling.
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia.
